A new class of weight-loss drugs has rattled global equity markets, sending shares of everything from food and beverage companies to medical-device makers tumbling. As earnings season kicks into high gear, firms are expected to reveal if consumer behaviors are being altered by the likes of Ozempic.

So far, fear has driven investors to sell consumer-exposed stocks. A basket of such companies — including Oreo cookies maker Mondelez International Inc. and Modelo beer producer Constellation Brand Inc. — is down nearly 9% since early August with losses roughly double those of the S&P 500 Index, while makers of things like insulin pumps have wiped out close to a third of their value over the same stretch amid concerns that fewer people will need their products.

  • Jo Miran
    92·
    1 year ago

    I discussed this with my wife at least two or three months ago. I’m glad to see Bloomberg continues to feed investors the stalest data possible.

      • Jo Miran
        81·
        1 year ago

        Meaning, that this has been on the news for months. Also, it’s not a dig on you, it’s a dig on Bloomberg. Instructional investors already have puts in place. Late articles like this just fuck the individual investors.

        EDIT: *institutional